Repligen sank -11.6% this afternoon, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Repligen has logged a -11.3% 52 week change, compared to 22.5% for the S&P 500
-
RGEN has an average analyst rating of buy and is -38.09% away from its mean target price of $204.08 per share
-
Its trailing earnings per share (EPS) is $0.27, which brings its trailing Price to Earnings (P/E) ratio to 467.9. The Health Care sector's average P/E ratio is 27.53
-
The company's forward earnings per share (EPS) is $2.01 and its forward P/E ratio is 62.9
-
The company has a Price to Book (P/B) ratio of 3.58 in contrast to the Health Care sector's average P/B ratio is 3.61
-
The current ratio is currently 7.0, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
RGEN has reported YOY quarterly earnings growth of -92.6% and gross profit margins of 0.5%
-
The company's free cash flow for the last fiscal year was $77.7 Million and the average free cash flow growth rate is 17.0%
-
Repligen's revenues have an average growth rate of 22.4% with operating expenses growing at 22.0%. The company's current operating margins stand at 8.5%